The comparison of outcomes between symptomatic individuals with and without chronic obstructive pulmonary disease (COPD) is one of the many research questions posed in a recent American Thoracic Society/European Respiratory Society statement (1) and represents the main thrust of this Pulmonary Perspective. We review the association between chronic respiratory symptoms, excess decline of FEV 1 , and development of COPD and the evidence for a potential new clinical entity in individuals with chronic respiratory symptoms and normal spirometry (postbronchodilator FEV 1 /FVC > 0.7). This subset of patients, roughly similar to the group previously labeled "stage 0" by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2) , suggests a category of symptomatic smokers with normal spirometry, but increased risk of poor outcomes. Notwithstanding, it is of note that other functional measures of earlier and more subtle changes in small peripheral airways have been investigated previously. In the 1960s, a large number of studies were devoted to identify susceptible smokers likely to progress to chronic airflow limitation (3) . In the 1970s, it was observed in young cigarette smokers that inflammation was evident in the small airways in the absence of pulmonary emphysema (4) . A better understanding of the biological mechanisms underlying symptoms in smokers with intact FEV 1 /FVC should improve our ability to treat respiratory symptoms that occur before the development of COPD.
GOLD 0: Splendor and Decline
Traditionally, the typical chronic respiratory symptoms of COPD are cough and sputum production, usually referred to as chronic bronchitis or chronic mucus hypersecretion (CMH; phlegm on most days at least 3 mo/yr for 2 yr). In the past, these were considered common in smokers and strongly related to chronic airflow limitation. In the 1980s, a follow-up study in men concluded that the risk of death from COPD was associated to the initial degree of airflow limitation, but not to CMH, supporting that airflow limitation and CMH were largely independent disease processes (5). These findings were, however, at variance with data from the Copenhagen City Heart Study cohort showing an association between CMH and mortality (6) and analyses of data, from two surveys 5 years apart, that concluded that CMH was significantly associated with an excess of FEV 1 decline (7).
In 2001, the first GOLD report (2) stated that a clinical diagnosis of COPD had to be confirmed by spirometry, and all values referred to post-bronchodilator FEV 1 /FVC. The GOLD document originally defined five spirometric stages (or grades [8] ): 0 and 1 (mild), 2 (moderate), 3 (severe), and 4 (very severe), a classification also endorsed by the American Thoracic Society/European Respiratory Society Task Force for COPD (9) . GOLD 0 or "at risk," namely, the sole presence of chronic cough and phlegm with normal spirometry, offered a unique opportunity to identify individuals at risk for COPD consistent with increased awareness among health care providers.
Traditionally, the natural history of COPD has been viewed as synonymous with decline in FEV 1 from early adulthood and throughout life, after the seminal work by Fletcher and Peto (10) . However, it was acknowledged that most smokers whose FEV 1 is already below the normal range for nonsmokers by early adulthood are at risk of death due to airflow limitation. Alternatively, the majority of smokers whose FEV 1 is still above average at this age are unlikely to develop severe airflow limitation. However, recent data from three large cohorts have confirmed that approximately half of the individuals with airflow limitation followed the hypothesis that implied a rapid FEV 1 decline within normal limits in early adulthood, whereas the other half had a rather normal FEV 1 decline at this age, but started from a low initial value of FEV 1 (11) , thus supporting the effect of early life events on the likelihood of having airflow limitation in adulthood.
Chronic Respiratory
Symptoms, Long-Term FEV 1 Decline, and COPD Development
In the 2006 GOLD revision (12), GOLD 0 was no longer included, as there was incomplete evidence that the individuals who meet GOLD 0 necessarily progress on to GOLD 11. Nonetheless, the importance of the public health message, to highlight that the presence of cough and sputum in the population is not normal, remained unchanged. GOLD 0 was discarded based on data from the Copenhagen City Heart Study cohort (13) , in which 7.1% of men and 4.8% of women (mean age, over 52 yr each) had GOLD 0 at baseline, with a prevalence of 6.1%. After 5 and 15 years, COPD developed in 13.2 and 20.5% of smokers with GOLD 0 at enrollment, respectively, although symptoms of cough and sputum in unobstructed smokers were associated with an excess lung function decline of 19 ml/yr, in addition to the FEV 1 reduction observed in unobstructed smokers without these symptoms. Despite these findings, the data from this study suggested that most of the cases of new airflow limitation were observed among subjects without symptoms of cough and sputum, and, consequently, it was believed that GOLD 0 was of little help in identifying subjects at risk for COPD.
Subsequently, the European Community Respiratory Health Survey Study (14) determined that the prevalence of GOLD 0 was 11.8% in a randomly selected population. Moderate to heavy smoking and second-hand tobacco exposure were significantly associated with GOLD 0 and GOLD 11. Individuals with GOLD 0 presented the same risks factors, including environmental tobacco exposure and childhood respiratory infections, as those with COPD with similar high percentages of healthcare resources, referred to as "breathing problems." In a cohort of middle-aged and elderly subjects with GOLD 0 (nonsmokers, 21%), the 10-year incidence of COPD was 13.5% (15) . Increasing age, smoking, and sputum production, but not sex, were risk factors for COPD, so GOLD 0 appeared to identify individuals at risk for COPD. The study from the large Atherosclerosis Risk in Communities cohort (16) of smokers and nonsmokers brought the novelty that patients with GOLD 0, defined by the association of any chronic respiratory symptom, including breathlessness with normal FEV 1 , had an increased risk of mortality. A parallel study of healthy, middle-aged men found an association between symptoms and risk of death when widening the GOLD 0 definition to subjects with any respiratory symptom (i.e., dyspnea) other than those of CMH alone (17) . A reassessment of the European Community Respiratory Health Survey Study cohort, alluded to previously here, determined the presence of CMH and shortness of breath and future occurrence of COPD (18) . It was concluded that the presence of CMH, but not dyspnea, identified individuals with a high risk of developing chronic airflow limitation, and was considered to be an early marker of COPD regardless of smoking habits. The prevalence of GOLD 0 was 6.2% in the Proyecto Latinoamericano de Investigación en Obstrucción Pulmonar study (19) . In that study, individuals with CMH had worse lung function and general health conditions with more respiratory symptoms (i.e., wheezing and dyspnea, limited physical activity, "COPD exacerbation-like" events, and use of respiratory medications). In the Tucson Epidemiological Study of Airway Obstructive Disease (20) , CMH at baseline significantly increased the risk for incident airflow limitation and all-cause mortality among individuals younger than 50 years old, but not among those subjects older than 50 years. The conclusion was that CMH with preserved FEV 1 in the former group may represent an early marker of susceptibility to COPD and all-cause mortality. In the Medical Research Council-National Survey of Health and Development, a prospective study of a representative cohort of women and men (21) , the prevalence of CMH alone among smokers at enrollment increased between ages 36 and 43 years from 7.6 (62.0) to 13.0 (62.6)%, respectively. At these ages, the prevalence of CMH was associated with a higher risk of subsequent airflow limitation with a dynamic, fluctuating pattern subject to decrease after smoking cessation to levels observed in never-smokers. Moreover, the longer individuals had symptoms, the higher the FEV 1 decline (Figure 1 ). The contention was that CMH in middle-aged smokers may modulate the early phase of COPD development and reflect activity of the chronic airway disease, a hypothesis that was challenged, given the background of different clinical and developmental phenotypes (22) .
Clinical and Radiographic Characteristics of Symptomatic, Unobstructed Individuals
Recent data from five large cohorts have characterized the clinical and radiographic features of symptomatic individuals with normal FEV 1 . From an urban population-based study (23) , two subsets of current smokers with normal spirometry were randomly selected and followed over 3-4 years. In the first group of 59 individuals with normal diffusing capacity of the lung for carbon monoxide (DL CO ), only 2 subjects (3%) developed significant reductions in FEV 1 /FVC and DL CO . In the second subset with 46 participants with low DL CO at baseline, 10 (22%) developed COPD. There were no respiratory clinical or radiographic differences between the two groups.
In the Canadian Cohort of Obstructive Lung Disease study (24) , the occurrence of "exacerbation-like" events in individuals with and without COPD was highlighted. Furthermore, compared with subjects with COPD, those without COPD had half the frequency of exacerbations and were independently associated with several risk factors (i.e., female sex, presence of wheezing, use of respiratory therapies, and poor health status). In individuals without COPD, those with exacerbations were more likely to have poorer healthrelated quality of life and missing social activities than those without exacerbations.
In parallel, the Genetic Epidemiology of COPD (COPDGene) study (25) determined similar acute events of respiratory disease, more common in current and former smokers. In a second study from this same COPDGene cohort, a large sample of unobstructed subjects was compared with patients with GOLD 11 and also with a cohort of never smokers (26) . One or more of seven predefined respiratory-related impairments (i.
Advancing age was associated with smoking cessation. Individuals with respiratory impairments were more likely to use common respiratory medication and exhibited worse manifestations. Of note, in the Multi-Ethnic Study of Atherosclerosis cohort study (27) , including participants (51% never-smokers) without airflow limitation, emphysema-like lung changes on cardiac CT were associated with all-cause mortality among subjects without airflow limitation, particularly among smokers.
Ever-or former smokers and neversmokers with normal FEV 1 from the very recent observational Subpopulations and Intermediate Outcome Measures in COPD Study cohort (28) were investigated. Chronic respiratory symptoms, based on a COPD Assessment Test (CAT) cutoff score of 10 or greater, were observed in 50% of smokers with a prevalence of CMH on the order of 33% alone in symptomatic smokers. Importantly, the use of CAT, a questionnaire designed for COPD (29) , provides a broader assessment of symptomatic burden than just respiratory symptoms. Compared with asymptomatic current or former smokers and never-smokers, symptomatic smokers were younger and more likely to be current smokers, and reported symptoms of CMH and a history of wheezing and asthma than those with lesser symptoms (CAT score ,10). Moreover, they had significantly less physical activity, slightly lower lung function, more respiratory exacerbations, and HRCT findings consistent with greater airway wall thickening and low percentage emphysema. These differences persisted, despite adjustment for reported comorbidities. There were no differences in the spectrum of symptoms between symptomatic smokers with normal FEV 1 and patients in GOLD 1-2.
Interestingly, the Exacerbations of Chronic Pulmonary Disease Tool-Patient Reported Outcome (30) approach, developed to identify and characterize exacerbations, provides a broader conceptual basis than just respiratory symptoms. Finally, the very recent development of the COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk tool (31) has suggested that a broader concept of symptoms than simple, focused respiratory symptoms is useful in identifying undiagnosed COPD. These concepts, including the prominent role of fatigue, may provide some insights into systemic effects of smoking and explain the greater clinical impact identified by recent work on symptomatic, unobstructed smokers than the original GOLD 0 label.
In summary, these data suggest that many individuals with respiratory symptoms, but without airflow limitation, have CT findings consistent with largeairway abnormalities, and these individuals experience significant morbidity and increased health care utilization, lending credence to the concept that the presence of chronic respiratory symptoms in unobstructed smokers represents a clinically significant entity. The weight of the evidence would suggest that a greater symptom burden, particularly those symptoms that are respiratory in nature, is a risk factor for rapid lung function decline, and therefore likely represents one form of early COPD. However, this likely only represents one pathway for COPD development, as other individuals without symptoms also go on to develop COPD. A study in smokers with GOLD 0-4 from the COPDGene cohort observed a significant association between functional small-airway disease, assessed by CT-parametric response mapping that identifies areas of nonemphysematous gas trapping, and FEV 1 decline over 5 years (32) . Small airways (,2 mm in diameter) are known to be the major site of narrowing in patients with COPD (33) , and disease in the small airways is thought to precede the onset of developing emphysematous lesions (34) . Although the signal was attenuated in unobstructed individuals as opposed to those with established airflow limitation, CT-assessed small-airway disease was still associated with more rapid lung function decline in this group. Notably, however, those unobstructed individuals with excess small-airway abnormality were not more symptomatic based on the presence of chronic bronchitis, again reinforcing the multiple trajectories toward the development of airflow limitation. This is further emphasized by data from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints cohort study, in which there was no association between CMH and long-term FEV 1 decline, whereas the presence of pulmonary emphysema was associated with CMH (35, 36) .
Clinical Significance and Remaining Questions
The new data on this clinical condition derived from these cohort studies (24, 26, 28) provide valuable insights into this condition as a distinct clinical entity, irrespective of whether it progresses to COPD. This subset of smokers is predominantly observed in middle-aged subjects, without sex differences. Breathlessness associated with limited physical activity and frequent COPD exacerbation-like events that require respiratory therapies constitute key clinical features. Moreover, it is associated with HRCT percentage airway wall thickness changes. Data from long-term longitudinal clinical studies described previously here (24, 26, 28) suggest that symptoms in unobstructed smokers are associated with higher risk for the future development of airflow limitation, even in the data that ultimately led to the withdrawal of GOLD 0 (13). However, passage through a GOLD 0 is not the only pathway to airflow limitation, and many patients with GOLD 0 do not necessarily progress to chronic airflow limitation.
Whatever the relevance and the robustness of the reported data, the list of shortcomings or unmet needs (Table 1) is large and overcome, in part, the established findings. Of note, however, is the observation that, in several of these studies (26, 28) , cough and phlegm production are not present in all smokers, suggesting that systemic symptoms (i.e., dyspnea, limited physical activity, fatigue) may be more representative of the broad effects of smoking per se. One conclusion is that the full breadth of symptoms associated with early lung disease in smokers has been underestimated and even unrecognized (37) . However, it could also be that, for example, muscles and the cardiovascular system were affected in these smokers. Accordingly, we likely need to reconsider the strategy of early diagnosis and preventative measures by paying more attention to symptoms. It has been observed that excess mortality in smokers is largely due to associations with diseases, such as renal failure, hypertensive heart disease, and respiratory diseases, not properly caused by smoking (38) .
Alternatively, these unmet needs bring opportunities for future research studies to enhance the understanding of the natural history of COPD, while further supporting preventative and therapeutic approaches. According to a retrospective analysis from primary and secondary care cohorts, opportunities to diagnose COPD at an earlier stage are being missed, particularly during the 5 years immediately before diagnosis (39) . These needs extend from the selection of appropriate cohorts of participants between population-based and disease-specific cohorts to include people with risk factors other than tobacco smoking, such as environmental and occupational exposures (40) . A skillful exploitation of tools, such as clinical symptoms (respiratory and nonrespiratory) and serum biomarkers (41) to assess disease activity (42) , including sensitive smallairway disease and exercise tests, may be complementary. Likewise, COPD exacerbation-like events and coexisting comorbidities need to be better characterized to provide new insights (43, 44) . Furthermore, the different HRCT patterns, combined with novel CT volumetric scans and other imaging novelties, have to be better investigated. The association between endothelial dysfunction, FEV 1 , and CT percentage of emphysema in former smokers with normal FEV 1 suggests that pulmonary vascular disturbances can be considerably involved in the development of emphysema (45) , which supports the potential role of pulmonary vessels in the pathogenesis of COPD (46) (47) (48) . Finally, because, in most smokers, respiratory and nonrespiratory symptoms may come before airflow limitation, we need to reconsider the strategy of early diagnosis and management to give, first, particular attention to symptoms. Last, but not least, pharmacologic and nonpharmacologic therapies to pave the way for the potential of personalized medicine (49) need also to be reassessed.
Conclusions
It is now time to move beyond GOLD 0 (50) to decipher the fundamental question regarding the short-and long-term clinical significance of the presence of chronic respiratory symptoms and preserved lung function. Indeed, the dilemma remains as to whether we are simply confronted with an "early phase" of what will become COPD in the traditional sense, or a separate, smoking-related condition, which is chronic and remains symptomatic without progression to COPD. Indeed, it is possible that both patterns occur. Research studies targeting this likely distinct condition in the context of the systemic effects of smoking by itself should certainly shed light on the current understanding of the natural history of COPD (37, 38) . n Author disclosures are available with the text of this article at www.atsjournals.org. 
